Amgen Inc stock page - price, fundamentals, dividends - iOCharts

Ticker
AMGN

Price
244.77
Stock movement up
+0.81 (0.33%)
Company name
Amgen Inc
Exchange
(NASDAQ
,
Currency
USD
)
Sector
Healthcare >
Drug Manufacturers-General
Market cap
130.76B
Ent value
182.51B
Price/Sales
4.97
Price/Book
142.75
Div yield
3.17%
Div growth
11.97%
Growth years
11
FCF payout
48.44%
Trailing P/E
22.85
Forward P/E
12.85
PEG
3.33
EPS growth
14.00%
1 year return
-2.84%
3 year return
12.99%
5 year return
9.15%
10 year return
13.23%
Last updated: 2022-05-19

DIVIDENDS

Dividend yield - 5y

Loading...
Dividend yield data
Dividend per share7.76
Dividend yield3.17%
Payout frequencyQuarterly
Maximum yield3.90%
Average yield2.95%
Minimum yield2.41%
Discount to avg yield7.08%
Upside potential7.62%
Yield as % of max yield81.25%

Yield distribution (inverse percentile) - 5y

Loading...
Yield distribution data
Dividend yield3.17%
Current yield distribution19.60%
Yield at 100% (Min)2.41%
Yield at 90%2.63%
Yield at 80%2.69%
Yield at 50% (Median)2.92%
Yield at 20%3.17%
Yield at 10%3.33%
Yield at 0% (Max)3.90%

Dividend per share

Loading...
Dividend per share data
Years of growth11 years
CCC statusDividend Contender
Dividend per share7.76
Payout frequencyQuarterly
Ex-div date16 May 2022
EPS (TTM)10.13
EPS (1y forward)19.05
EPS growth (5y)14.00%
EPS growth (5y forward)6.87%

Dividend growth

Loading...
Please create a free account or log in to access this chart
Dividend growth data
AMGNS&P500
DGR MR10.23%-16.52%
DGR TTM10.12%4.37%
DGR 3 years10.06%3.88%
DGR 5 years11.97%4.73%
DGR 10 years-8.30%
DGR 15 years-5.82%
Time since last change announced168 days
EPS growth (5y)14.00%
EPS growth (5y forward)6.87%

Payout ratio

Loading...
Please create a free account or log in to access this chart
Payout ratio data
EPS coverageFCF coverage
TTM71.24%48.44%
Average--
Forward40.73%-

VALUATION

Valuation Ratios

Loading...
Valuation Ratios data
Trailing P/E22.85
Price to OCF14.03
Price to FCF15.53
Price to EBITDA11.75
EV to EBITDA16.41

Valuation (Sales/Book Value)

Loading...
Valuation (Sales/Book Value) data
Price to Sales4.97
Price to Book142.75
EV to Sales6.94

FINANCIALS

Per share

Loading...
Per share data
Current share count534.20M
EPS (TTM)10.13
FCF per share (TTM)14.90

Income statement

Loading...
Income statement data
Revenue (TTM)26.32B
Gross profit (TTM)19.79B
Operating income (TTM)8.01B
Net income (TTM)5.72B
EPS (TTM)10.13
EPS (1y forward)19.05

Margins

Loading...
Margins data
Gross margin (TTM)75.21%
Operating margin (TTM)30.44%
Profit margin (TTM)21.75%

Balance Sheet

Loading...
Please create a free account or log in to access this chart
Balance Sheet data
Cash6.53B
Net receivables5.08B
Total current assets18.52B
Goodwill14.90B
Intangible assets14.57B
Property, plant and equipment0.00
Total assets59.20B
Accounts payable1.40B
Short/Current long term debt36.85B
Total current liabilities12.89B
Total liabilities58.28B
Shareholder's equity916.00M
Net tangible assets-28.55B

Cash flow

Loading...
Please create a free account or log in to access this chart
Cash flow data
Operating cash flow (TTM)9.32B
Capital expenditures (TTM)904.00M
Free cash flow (TTM)8.42B
Dividends paid (TTM)4.08B

Financial returns

Loading...
Please create a free account or log in to access this chart
Financial returns data
Return on Equity624.78%
Return on Assets9.67%
Return on Invested Capital15.15%
Cash Return on Invested Capital22.28%

STOCK INFORMATION

Stock chart

Loading...
Stock price data
Open242.35
Daily high245.86
Daily low241.86
Daily Volume2.34M
All-time high260.95
1y analyst estimate249.25
Beta0.59
EPS (TTM)10.13
Dividend per share7.76
Ex-div date16 May 2022
Next earnings date1 Aug 2022

Downside potential

Loading...
Downside potential data
AMGNS&P500
Current price drop from All-time high-6.20%-18.47%
Highest price drop-60.17%-56.47%
Date of highest drop15 Jul 20029 Mar 2009
Avg drop from high-17.85%-11.34%
Avg time to new high24 days12 days
Max time to new high1773 days1805 days
COMPANY DETAILS
AMGN (Amgen Inc) company logo
Marketcap
130.76B
Marketcap category
Large-cap
Description
Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. It focuses on inflammation, oncology/hematology, bone health, cardiovascular disease, nephrology, and neuroscience areas. The company's products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Neulasta that reduces the chance of infection due a low white blood cell count in patients cancer; Prolia to treat postmenopausal women with osteoporosis; Xgeva for skeletal-related events prevention; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Aranesp to treat a lower-than-normal number of red blood cells and anemia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; and Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization. It also markets Nplate, Vectibix, MVASI, Parsabiv, EPOGEN, KANJINTI, BLINCYTO, Aimovig, EVENITY, AMGEVITATM, Sensipar/Mimpara, NEUPOGEN, IMLYGIC, Corlanor, and AVSOLA. Amgen Inc. serves healthcare providers, including physicians or their clinics, dialysis centers, hospitals, and pharmacies. It distributes its products through pharmaceutical wholesale distributors, as well as direct-to-consumer channels. It has collaboration agreements with Novartis Pharma AG; UCB; Bayer HealthCare LLC; BeiGene, Ltd.; Eli Lilly and Company; Datos Health; and Verastem, Inc. to evaluate VS-6766 in combination with lumakrastm (Sotorasib) in patients with KRAS G12C-mutant non-small cell lung cancer. It has an agreement with Kyowa Kirin Co., Ltd. to jointly develop and commercialize KHK4083, a Phase 3-ready anti-OX40 fully human monoclonal antibody for the treatment of atopic dermatitis and other autoimmune diseases; and research and development collaboration with Neumora Therapeutics, Inc. and Plexium, Inc. Amgen Inc. was incorporated in 1980 and is headquartered in Thousand Oaks, California.
Employees
24200
Investor relations
SEC filings
CEO
Robert Bradway
Country
USA
City
Thousand Oaks
Stock type
Common stock
CCC status
Dividend Contender
Dividend Frequency
Quarterly
EVENTS AND PRESENTATIONS
EventsPresentations
Loading...
UNDERSTAND THE BUSINESS
Loading...
COMPANY NEWS
All newsPress releases
As concerns over a looming recession grow, these are some blue-chip stocks to buy that could help decrease portfolio volatility. 3M (MMM): The recent purchase of LeanTec could improve long-term growth...
May 17, 2022
BridgeBio (BBIO) forms an exclusive partnership with Bristol Myers (BMY) to develop and commercialize its SHP2 inhibitor.
May 13, 2022
Amgen, Altria Group, Uber Technologies, Microchip Technology, and Arista Networks are part of Zacks top Analyst Blog.
May 13, 2022
Today's Research Daily features new research reports on 16 major stocks, including Amgen Inc. (AMGN), Altria Group, Inc. (MO), and Uber Technologies, Inc. (UBER).
May 12, 2022
Amgen (NASDAQ:AMGN) and Otezla® (apremilast) have partnered with pop icon and entrepreneur Lance Bass, for the Double Take campaign to empower people to take action when it comes to psoriatic arthriti...
May 12, 2022
Readers hoping to buy Amgen Inc. ( NASDAQ:AMGN ) for its dividend will need to make their move shortly, as the stock is...
May 12, 2022
Let's take a look at some big biotechnological earnings releases to see if these will impact ETFs exposed to the space.
May 10, 2022
Amgen (NASDAQ:AMGN) will present at the 2022 Bank of America Healthcare Conference at 12:20 p.m. ET on Wednesday, May 11, 2022. David M. Reese, M.D., executive vice president of Research and Developme...
May 6, 2022
Radius (RDUS) posts a y/y wider Q1 loss and misses revenue estimates.
May 6, 2022
Adding defensive healthcare stocks can be a great way to ride out continued volatility in the market. AbbVie (ABBV): Investors are overreacting to this venerable big pharma company’s recent earnings r...
May 6, 2022
Next page